Curative Financial Statements From 2010 to 2026

CUBT Stock  USD 0  0.0006  12.24%   
Analyzing historical trends in various income statement and balance sheet accounts from Curative Biotechnology's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Curative Biotechnology's valuation are summarized below:
Gross Profit
100.2 K
Market Capitalization
4.5 M
Revenue
132.3 K
There are currently one hundred twenty fundamental signals for Curative Biotechnology that can be evaluated and compared over time across rivals. All traders should validate Curative Biotechnology's prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 13.3 M in 2026. Enterprise Value is likely to gain to about 15.4 M in 2026

Curative Biotechnology Total Revenue

0.0

Check Curative Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Curative Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 111.3 K, Interest Expense of 1.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 55.01, Dividend Yield of 0.0 or Days Sales Outstanding of 267. Curative financial statements analysis is a perfect complement when working with Curative Biotechnology Valuation or Volatility modules.
  
Build AI portfolio with Curative Stock
Check out the analysis of Curative Biotechnology Correlation against competitors.
For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.

Curative Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding1.1 BB447.4 M
Slightly volatile
Total Current Liabilities8.5 M8.1 M2.3 M
Slightly volatile
Other Liabilities523.9 K649.7 K531.2 K
Slightly volatile
Accounts PayableM4.7 M1.5 M
Slightly volatile
Common Stock78.6 K82.7 K456.4 K
Slightly volatile
Property Plant Equipment11.7 KK10 K
Slightly volatile
Total Assets2.6 M2.5 M1.1 M
Slightly volatile
Short and Long Term Debt Total1.7 M1.6 M684.8 K
Slightly volatile
Property Plant And Equipment NetK2.2 K14.7 K
Slightly volatile
Non Current Assets Total2.4 M2.2 M774 K
Slightly volatile
Cash And Short Term Investments21.3 K22.5 K98.5 K
Pretty Stable
Liabilities And Stockholders Equity2.6 M2.5 M1.1 M
Slightly volatile
Other Current Assets298.8 K173.1 K742.4 K
Very volatile
Other Stockholder Equity44.5 M42.4 M13.5 M
Slightly volatile
Total Liabilities6.1 M8.1 M4.9 M
Slightly volatile
Short Term Debt1.7 M1.6 M617.1 K
Slightly volatile
Intangible Assets1.6 M1.6 M459.7 K
Slightly volatile
Other Assets0.860.932.8 K
Very volatile
Short and Long Term Debt1.3 M1.2 M571.4 K
Slightly volatile
Capital Stock49.5 K52.2 K208.1 K
Slightly volatile
Good Will129.8 K136.6 K158.1 K
Pretty Stable
Property Plant And Equipment Gross5.8 K6.2 K55.1 K
Slightly volatile
Deferred Long Term Liabilities74.4 K83.7 K91.3 K
Slightly volatile

Curative Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization111.3 K106 K36.5 K
Slightly volatile
Other Operating Expenses1.6 M2.8 M1.5 M
Slightly volatile
Cost Of Revenue59 K83 K73.4 K
Slightly volatile
Total Operating Expenses1.5 M2.7 M1.4 M
Slightly volatile
Selling General Administrative1.5 M2.6 M1.1 M
Slightly volatile
Selling And Marketing Expenses12.6 K14.9 K12.3 K
Slightly volatile
Reconciled Depreciation6.6 K9.1 K6.2 K
Slightly volatile

Curative Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation88.7 K106 K78.8 K
Slightly volatile
Stock Based Compensation195.2 K205.5 KM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio55.0152.3947.1618
Slightly volatile
Days Sales Outstanding267254218
Slightly volatile
Average Payables523.5 K284.6 K460.1 K
Slightly volatile
Capex To Depreciation0.170.183.9165
Slightly volatile
EV To Sales71.9268.4954.5546
Slightly volatile
Inventory Turnover0.210.221.7783
Slightly volatile
Days Of Inventory On Hand1.4 K1.3 KK
Slightly volatile
Payables Turnover0.03910.02570.0604
Slightly volatile
Sales General And Administrative To Revenue0.290.560.4735
Slightly volatile
Capex To Revenue0.10.120.1298
Slightly volatile
Cash Per Share0.00.02.0E-4
Pretty Stable
Days Payables Outstanding17.8 K18.8 K49.7 K
Very volatile
Intangibles To Total Assets0.490.560.5537
Slightly volatile
Current Ratio0.03270.03440.8698
Pretty Stable
Receivables Turnover1.111.1643.3765
Pretty Stable
Capex Per Share0.00.01.0E-4
Slightly volatile
Average Receivables26.7 K52 K40.8 K
Pretty Stable
Revenue Per Share0.00.05.0E-4
Slightly volatile
Interest Debt Per Share0.00260.00250.0015
Slightly volatile
Debt To Assets0.690.731.3993
Slightly volatile
Operating Cycle1.7 K1.6 K1.2 K
Slightly volatile
Days Of Payables Outstanding17.8 K18.8 K49.7 K
Very volatile
Quick Ratio0.03270.03440.8514
Very volatile
Net Income Per E B T0.80.90.9823
Slightly volatile
Cash Ratio0.00240.00250.1344
Pretty Stable
Days Of Inventory Outstanding1.4 K1.3 KK
Slightly volatile
Days Of Sales Outstanding267254218
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.421.181.3994
Slightly volatile
Fixed Asset Turnover2.132.244.9772
Slightly volatile
Debt Ratio0.690.731.3993
Slightly volatile
Price Sales Ratio55.0152.3947.1618
Slightly volatile
Asset Turnover0.180.190.5838
Slightly volatile

Curative Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13.3 M12.7 M6.6 M
Slightly volatile
Enterprise Value15.4 M14.7 M7.5 M
Slightly volatile

Curative Fundamental Market Drivers

About Curative Biotechnology Financial Statements

Curative Biotechnology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Curative Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Curative Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Curative Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-3.1 M-3 M
Cost Of Revenue83 K59 K
Sales General And Administrative To Revenue 0.56  0.29 
Capex To Revenue 0.12  0.10 
Ebit Per Revenue(0.12)(0.13)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.